United Kingdom
Touchlight, with its slogan "DNA is our DNA™", is at the forefront of the genetic medicine revolution, serving as a CDMO that specializes in enzymatic GMP DNA production. Founded in 2008, the company is positioned to transform the landscape of genetic therapies by offering innovative, scalable alternatives to traditional plasmid DNA (pDNA) methods.
Having set industry benchmarks with the acceptance of its FDA Drug Master File in 2022 and achieving the world's first cell-free DNA GMP license by 2025, Touchlight stands as a key enabler in AAV, mRNA, DNA vaccine, and gene editing technologies. Their facility's acclaim, underscored by ISPE’s Facility of the Year Awards for Innovation, demonstrates its state-of-the-art capabilities.
With multiple client products in clinical stages, Touchlight offers compelling evidence-based synthetic DNA manufacturing, addressing speed, scalability, and sustainability needs of contemporary genetic medicine. Investors should note its critical role in maintaining momentum for future genetic therapies innovation.
